Vaccine and Immunology

Welcome Message

We are pleased to invite you to the “8^th World Conference on Vaccine and Immunology”, scheduled for June 15–16, 2026 in Paris, France. Under the theme “Innovations in Vaccines and Immunology: Shaping the Future of Global Health,” this conference will bring together leading researchers, scientists, healthcare professionals, and industry experts from around the world.

The conference will serve as a global platform to share the latest research, advancements, and innovations in vaccine development and immunological science. Participants will engage in keynote presentations, scientific sessions, and interactive discussions focused on emerging trends and challenges in disease prevention and immune research.

Join us in Paris for two days of knowledge exchange, collaboration, and networking aimed at advancing immunology research and strengthening global health initiatives.

Target Audience:

• Immunologists
• Vaccine Researchers and Scientists
• Microbiologists and Virologists
• Epidemiologists
• Clinical Researchers
• Public Health Professionals
• Pharmaceutical Industry Professionals
• Biotechnology Experts
• Medical Practitioners and Physicians
• Academic Professors and Scholars in Life Sciences
• Research Fellows and Postdoctoral Researchers
• Vaccine Manufacturers and Developers
• Healthcare Policy Makers and Regulatory Authorities
• Laboratory Technologists and Research Analysts
• Undergraduate, Graduate, and PhD Students in Biomedical and Life Sciences

About Conference

Join us for the 8^th World Conference on Vaccine and Immunology, scheduled for June 15–16, 2026 in Paris, France. This year’s theme, “Innovations in Vaccines and Immunology: Shaping the Future of Global Health,” highlights recent advancements and emerging discoveries in vaccine development and immunological research.

The conference will bring together leading immunologists, vaccine researchers, healthcare professionals, scientists, and industry experts from across the globe to share knowledge and discuss the latest scientific progress in immunology and disease prevention. The program will feature keynote lectures, oral and poster presentations, panel discussions, and interactive sessions that encourage collaboration and knowledge exchange.

Participants will have the opportunity to present their research, explore new technologies in vaccine science, and engage with distinguished experts in the field. This conference provides an excellent platform for networking, learning, and fostering collaborations that contribute to improving global health and advancing immunological research.

Why to Attend

World Vaccine Meet 2026 is the premier platform to connect with a global community of immunologists, vaccine researchers, healthcare professionals, and industry leaders. The conference will showcase the latest innovations, research breakthroughs, and emerging trends in vaccine development, immunology, infectious disease prevention, and global immunization strategies.

During the two-day event, participants will have the opportunity to present their research, exchange ideas, and engage in interactive sessions with leading experts in the field. Whether you are a seasoned researcher, healthcare practitioner, academician, or early-career scientist, World Vaccine Meet 2026 provides an invaluable opportunity to learn about cutting-edge developments, explore novel vaccine technologies, and collaborate on solutions that advance global health and strengthen public immunization programs worldwide.

Sessions & Tracks

Track 1: Immunotherapy & Immune Modulation

Immunotherapy and immune modulation involve therapeutic strategies that enhance or regulate the body’s immune system to treat diseases. This track focuses on approaches such as immune checkpoint therapies, cytokine-based treatments, and methods that control immune responses in various conditions. These therapies are important in the treatment of cancer, autoimmune disorders, and infectious diseases. Researchers study immune pathways and mechanisms to develop targeted and effective treatments. Advances in immunology and biotechnology continue to support the development of innovative immune-based therapies, helping improve patient outcomes through safer, more precise, and personalized medical interventions.

Track 2: Pediatric & Neonatal Vaccines

Pediatric and neonatal vaccines are essential for protecting infants, newborns, and children from serious infectious diseases. This track focuses on the development, safety, and effectiveness of vaccines designed specifically for early stages of life. It includes discussions on recommended immunization schedules, vaccine coverage, and strategies to improve vaccine accessibility and acceptance. Researchers also examine immune responses in infants and the development of safer and more effective vaccine formulations. These vaccines play a vital role in preventing diseases such as measles, polio, and hepatitis. Ongoing research and innovation continue to strengthen global immunization programs and improve child health outcomes.

Track 3: Infectious Disease Vaccines

Infectious Disease Vaccines focuses on the development of vaccines designed to prevent bacterial, viral, and parasitic infections that pose significant global health challenges. It highlights innovative vaccine platforms, novel antigen targets, and improved immunization strategies aimed at enhancing protection and long-term immunity. Researchers explore advancements in vaccine design, clinical trials, and global vaccination programs to combat emerging and re-emerging infectious diseases. The track also emphasizes the importance of rapid vaccine development and equitable distribution to reduce disease burden worldwide.

• Bacterial Vaccines
• Parasitic Disease Vaccines
• Emerging and Re-emerging Infectious Diseases
• Vaccine Development Technologies

Track 4: Cancer Vaccines

Cancer vaccines focus on both therapeutic and preventive approaches to stimulate the immune system against tumor cells. These vaccines target specific tumor-associated antigens to enhance immune recognition and destruction of cancer cells. Research in this track includes peptide-based vaccines, dendritic cell vaccines, and nucleic acid–based platforms designed to induce strong, durable anti-tumor responses. Emphasis is placed on improving vaccine efficacy, personalizing treatments, and combining vaccines with other immunotherapies such as checkpoint inhibitors. Advances in understanding tumor immunology and immune evasion mechanisms are driving the development of safer, more effective cancer vaccines that aim to prevent tumor growth and improve patient outcomes.

Track 5: Emerging Infectious Diseases

Emerging Infections Diseases focuses on vaccine research and control strategies for newly emerging or rapidly spreading infectious diseases that pose significant global health threats. It covers the identification of novel pathogens, understanding transmission dynamics, and rapid development of effective vaccines. Researchers explore innovative platforms, such as mRNA and viral vector vaccines, to accelerate response to outbreaks. Emphasis is also placed on surveillance, preparedness, and global vaccination strategies to contain epidemics and prevent pandemics. By studying emerging infectious diseases, scientists aim to enhance public health responses, improve vaccine accessibility, and develop effective preventive measures to protect populations from new and re-emerging infectious threats.

Track 6: Vaccine Adjuvants & Delivery

Novel vaccine adjuvants and advanced delivery systems are crucial for enhancing immune responses and improving vaccine efficacy. Innovative technologies such as nanoparticles, liposomes, and other carriers help stabilize antigens, enable targeted delivery, and allow controlled release. Research emphasizes strategies to boost immunogenicity while maintaining safety and minimizing side effects. Mucosal, targeted, and personalized delivery approaches are explored to create vaccines that are more effective, long-lasting, and adaptable for diverse infectious diseases and population needs.

• Novel Adjuvant Development
• Nanoparticle & Liposomal Delivery
• Mucosal & Targeted Delivery
• Controlled Release Formulations
• Immunogenicity Optimization

Track 7: Global Immunization Programs

Global immunization programs aim to prevent vaccine-preventable diseases by improving coverage and access worldwide. They involve planning public health initiatives, evaluating national and international vaccination efforts, and addressing challenges such as vaccine hesitancy and supply chain issues. Collaboration between governments, healthcare providers, and international organizations ensures equitable vaccine distribution. Research and policy development support sustainable strategies to enhance immunization outcomes. Strengthening these programs helps protect populations, prevent outbreaks, and promote global public health by ensuring vaccines reach all communities, particularly those at highest risk.

Track 8: Vaccine Safety & Clinical Trials

Vaccine development depends on rigorous clinical trials to ensure safety, efficacy, and regulatory compliance. This includes designing trial protocols, monitoring adverse events, and evaluating immune responses across populations. Regulatory standards guide data collection, reporting, and trial conduct to maintain quality and transparency. Post-marketing surveillance further tracks real-world safety and effectiveness. Innovations such as adaptive and multi-center trials help accelerate development while maintaining strict safety standards, ensuring that vaccines delivered to global populations are both effective and safe for widespread use.

Track 9: Autoimmune & Immune Disorders

Immune system dysfunction can lead to autoimmune and other immune-related disorders, causing the body to attack its own tissues. Research focuses on understanding disease mechanisms, identifying biomarkers, and developing targeted therapies to manage or prevent these conditions. Advances in immunology and biotechnology enable novel interventions to modulate immune responses safely and effectively, improving patient outcomes and quality of life.

• Autoimmune Disease Mechanisms
• Immunodeficiency Disorders
• Targeted Immune Therapies
• Biomarkers & Diagnostics
• Novel Immunomodulatory Strategies

Track 10: Respiratory & Influenza Vaccines

Vaccines targeting respiratory pathogens aim to prevent infections caused by influenza viruses, respiratory syncytial virus (RSV), and other respiratory viruses. Research focuses on improving vaccine efficacy, formulation, and delivery methods to enhance immune protection. Strategies include strain selection, adjuvant use, and seasonal immunization programs to reduce disease burden. Efforts also address challenges such as viral mutation, vaccine coverage, and population-specific immune responses. Advancements in respiratory vaccine development help decrease hospitalizations, limit outbreaks, and improve public health outcomes worldwide.

Track 11: Tropical & Neglected Disease Vaccines

Vaccines targeting tropical and neglected diseases address infections that disproportionately affect populations in low-resource regions. Research focuses on diseases such as malaria, dengue, chikungunya, leishmaniasis, and other neglected tropical infections. Efforts include identifying novel antigens, developing effective formulations, and optimizing delivery systems suitable for challenging environments. Strategies also emphasize accessibility, affordability, and culturally appropriate immunization programs. Advancing vaccines for these diseases helps reduce morbidity and mortality, promotes health equity, and strengthens global public health by protecting vulnerable and underserved populations from preventable infectious diseases.

Track 12: Next-Gen Vaccines

Next-generation vaccines leverage advanced technologies to enhance immune protection and adaptability. Platforms include mRNA & DNA vaccines, viral vector-based vaccines, and universal vaccine designs targeting multiple strains or pathogens. Research explores improving stability, delivery, and immunogenicity while reducing side effects. These innovations accelerate vaccine development, enable rapid responses to emerging infectious diseases, and support personalized immunization strategies. Continuous advancement in next-gen platforms promises more effective, durable, and broad-spectrum vaccines, transforming prevention and global health outcomes.

• mRNA & DNA Vaccines
• Viral Vector-Based Vaccines
• Universal Vaccine Platforms
• Rapid Response Vaccine Technologies
• Personalized Vaccine Strategies

Track 13: Nanotechnology in Vaccines

Nanotechnology offers innovative approaches to enhance vaccine delivery, stability, and immune activation. Nanomaterials and nanocarriers, such as liposomes, polymeric nanoparticles, and virus-like particles, improve antigen presentation, targeted delivery, and controlled release. These technologies boost immunogenicity while reducing side effects and enabling lower-dose formulations. Research also explores combining nanotechnology with novel adjuvants and next-generation vaccine platforms to optimize efficacy. By integrating nanoscience with immunology, vaccines can become more precise, durable, and adaptable, providing advanced solutions for infectious diseases, cancer immunotherapy, and emerging global health challenges.

Track 14: Antibody & Monoclonal Therapeutics

Therapeutic antibodies and monoclonal antibody technologies play a pivotal role in preventing and treating a wide range of diseases, including cancer, infectious diseases, and autoimmune disorders. Research focuses on antibody design, engineering, and optimization to enhance specificity, efficacy, and safety. Novel approaches include bispecific antibodies, antibody-drug conjugates, and humanized monoclonal antibodies. These therapies can neutralize pathogens, modulate immune responses, or target disease-specific cells. Advances in antibody therapeutics continue to expand personalized medicine, offering precise, effective, and adaptable treatment options for diverse clinical challenges.

• Monoclonal Antibody Development
• Bispecific & Multispecific Antibodies
• Antibody-Drug Conjugates
• Therapeutic Antibodies in Infectious Diseases
• Immunomodulatory Antibody Strategies

Track 15: Personalized & Immunogenetic Vaccines

Personalized and immunogenetic vaccines tailor immunization strategies to an individual’s genetic makeup, immune status, and biomarker profiles. These approaches optimize vaccine efficacy, safety, and durability by considering host-specific factors that influence immune responses. Research focuses on identifying predictive biomarkers, designing individualized vaccine formulations, and integrating next-generation technologies like mRNA and vector-based platforms. Personalized vaccines have applications in infectious diseases, cancer, and autoimmune disorders, enabling precision prevention and therapy. By aligning vaccination strategies with individual immunogenetic profiles, these vaccines aim to maximize protection, minimize adverse effects, and advance precision medicine in immunology.

Track 16: Bioinformatics & Big Data in Immunology

Computational tools and big data analytics are transforming vaccine design and immunology research. This track explores the use of bioinformatics to analyze immune responses, identify novel antigens, and predict vaccine efficacy. Techniques include genomics, proteomics, machine learning, and systems biology to model host-pathogen interactions and optimize immunization strategies. Large-scale data integration helps track disease outbreaks, evaluate population immunity, and accelerate vaccine development. By leveraging computational approaches, researchers can design more effective, targeted, and rapid vaccines, advancing precision immunology and improving global health outcomes.

Track 17: Post-Vaccination Monitoring

Post-vaccination monitoring ensures vaccines remain safe, effective, and impactful over time. It includes surveillance systems to track immunization coverage, monitor adverse events, and detect rare or delayed side effects. Researchers assess long-term effectiveness, population immunity, and factors affecting waning protection. Data from post-marketing studies guide policy decisions, optimize immunization programs, and support public confidence. Continuous monitoring enables rapid responses to safety concerns, informs booster recommendations, and strengthens global vaccination efforts.

• Vaccine Safety Surveillance
• Adverse Event Reporting & Analysis
• Long-Term Effectiveness Studies
• Population Immunity Assessment
• Policy & Program Optimization

Track 18: Vaccine Manufacturing & Supply Chain

Vaccine manufacturing and supply chain management ensure safe, effective, and timely delivery of vaccines worldwide. This track covers production technologies, quality control, and regulatory compliance to maintain vaccine potency. Efficient logistics and distribution systems, including cold-chain management, are essential to preserve stability during transport and storage. Strategies focus on minimizing wastage, improving accessibility, and supporting global immunization programs. Optimizing the entire supply chain from production to administration ensures vaccines reach populations safely, reliably, and efficiently, strengthening public health outcomes.

Track 19: Regulatory Affairs & Licensing

Regulatory affairs and licensing ensure vaccines and immunotherapies meet safety, efficacy, and quality standards. This track covers regulatory pathways, policy frameworks, and approval processes across national and international agencies. Key areas include clinical trial compliance, documentation, and post-marketing requirements. Understanding these processes accelerates vaccine availability while maintaining public trust and adherence to legal and ethical standards. Effective regulatory strategies support innovation, streamline approvals, and ensure that safe and effective vaccines reach populations worldwide.

Track 20: One Health Vaccinology

One Health vaccinology links human, animal, and environmental health to prevent and control infectious diseases. It addresses zoonotic transmission, emerging infections, and ecosystem impacts. Research includes vaccines for humans and animals, surveillance systems, and strategies considering environmental factors. Collaboration across medical, veterinary, and public health sectors improves early detection, outbreak prevention, and global health security. By integrating these domains, One Health approaches enable sustainable, comprehensive interventions that reduce disease burden and enhance public health worldwide.

• Zoonotic Disease Vaccines
• Animal-Human Transmission Studies
• Ecosystem-Based Immunization Strategies
• Surveillance & Early Warning Systems
• Integrated Health Approaches

Track 21: Immunological Biomarkers & Diagnostics

Immunological biomarkers and diagnostics are essential for evaluating immune responses, detecting diseases, and assessing vaccine efficacy. This track explores immune profiling, predictive and prognostic markers, and advanced diagnostic tools that guide vaccine development and clinical decision-making. Researchers focus on identifying reliable biomarkers to monitor immune protection, disease progression, and therapeutic responses. These technologies enable precision immunology, personalized vaccination strategies, and improved patient outcomes, supporting the design of safer and more effective vaccines while enhancing public health surveillance and disease management.

Track 22: Vaccine Awareness & Hesitancy

Vaccine awareness and hesitancy impact immunization coverage and public health outcomes. This track examines public perception, misinformation, and sociocultural factors that influence vaccine acceptance. Strategies include education campaigns, community engagement, and evidence-based communication to build trust and improve uptake. Researchers and policymakers study behavioral interventions and outreach programs to address concerns and overcome barriers. Strengthening awareness and reducing hesitancy ensures higher vaccination rates, protects populations from preventable diseases, and supports the success of national and global immunization programs.

Track 23: Therapeutic Vaccine Platforms

Therapeutic vaccine platforms are designed to treat existing diseases by stimulating targeted immune responses. This track covers vaccines for cancer, chronic infections, and autoimmune disorders, focusing on antigen selection, delivery methods, and immune modulation strategies. Research includes peptide-based, nucleic acid, and cellular vaccine technologies aimed at enhancing efficacy and durability. These vaccines can complement other therapies, improve clinical outcomes, and offer personalized treatment options. Advancements in therapeutic vaccine platforms are transforming disease management by enabling precise, immune-driven interventions for challenging health conditions.

• Cancer Therapeutic Vaccines
• Chronic Infection Vaccines
• Autoimmune Disease Vaccines
• Antigen Design & Delivery Platforms
• Immune Response Optimization

Track 24: Pandemic Preparedness & Response

Pandemic preparedness and response focus on rapid vaccine development, effective outbreak control, and coordinated global health strategies. This track covers surveillance systems, emergency manufacturing, and distribution networks to respond to emerging infectious threats. Researchers and policymakers study lessons from past pandemics to improve early detection, mitigation, and vaccination strategies. Emphasis is placed on international collaboration, risk assessment, and scalable interventions. Strengthening preparedness ensures timely, efficient, and equitable responses, minimizing disease spread and protecting populations during global health emergencies.

Track 25: Advancements in Vaccine Research & Development

Advancements in vaccine research and development drive innovation in preventing and treating infectious and chronic diseases. This track highlights emerging technologies, novel vaccine platforms, and innovative research methods that accelerate discovery and improve efficacy. Areas of focus include antigen design, computational modeling, next-generation delivery systems, and translational research. Breakthroughs in these fields enable rapid responses to emerging pathogens, personalized vaccination strategies, and more effective global immunization programs. Continuous innovation ensures the future of vaccinology remains adaptive, precise, and capable of addressing evolving public health challenges.

• Novel Vaccine Platform
• Antigen Discovery & Design
• Translational & Preclinical Research
• Computational & AI-Driven Approaches
• Innovative Clinical Trial Designs

Market Analysis

The global vaccines and immunology sector is experiencing steady expansion, driven by increasing demand for preventive healthcare and advancements in vaccine technologies. The global vaccines market was valued at approximately US$79.1 billion in 2024 and is projected to reach US$136.4 billion by 2034, growing at a CAGR of 5.6%. This growth is fueled by rising awareness of infectious disease prevention, expanded immunization programs, and continuous innovation in vaccine development platforms.

Technological breakthroughs such as mRNA vaccines, viral vector platforms, and recombinant vaccines have significantly accelerated research and development in vaccinology. mRNA-based vaccines alone accounted for the largest share of the market due to their rapid development capability and high efficacy. In addition, increasing investments in biotechnology and pharmaceutical research are enabling the development of next-generation vaccines targeting diseases such as cancer, HIV, malaria, and respiratory infections.                       

Regionally, North America dominates the global vaccine market, accounting for over 42% of total revenue, supported by strong research infrastructure, regulatory support, and the presence of major pharmaceutical companies. Meanwhile, the Asia-Pacific region is expected to witness the fastest growth due to expanding healthcare infrastructure, large-scale vaccination initiatives, and rising public–private partnerships.

Overall, growing global health initiatives, pandemic preparedness strategies, and innovations in immunology research are expected to strengthen the vaccine market, creating significant opportunities for researchers, healthcare professionals, and biotechnology companies worldwide.

Participation & Presentation Options

Oral Presentation: Oral presentations at World Vaccine Meet 2026 are open to research-based, theoretical, clinical, professional, and practice-oriented topics related to vaccines, immunology, infectious diseases, immunotherapy, epidemiology, and public health. Individuals with practical experience are also welcome to share insights that can positively impact clinical practice and global health outcomes.

• Speaker Slot: 30 minutes (20–25 minutes presentation + Q&A session)
• Keynote Slot: 40–45 minutes, followed by discussion

Workshop Presentation: Workshop Presentation: Workshops will focus on advanced clinical approaches, innovative techniques, hands-on demonstrations, and interactive learning in women’s healthcare.

• Duration: 45–50 minutes
• Team presentations are encouraged.
• Group presenters may be eligible for special registration benefits.

Poster Presentation: The Poster Competition at World Vaccine Meet 2026 encourages students, early-career researchers, and healthcare professionals to present original research.

• 20–25 minutes presentation (including Q&A)
• Evaluation by a judging panel
• Posters must be printed (1m x 1m dimensions)

This competition provides an excellent opportunity to gain visibility, receive feedback, and strengthen interdisciplinary research skills.

Webinar Presentation: For participants unable to attend in person, the conference offers a virtual presentation option. Presenters may submit pre-recorded video presentations to be featured during the official webinar sessions.

E-Poster Presentation: E-Posters are available for remote participants and will be displayed on the official conference platform. Accepted abstracts will be published in the conference proceedings with DOI indexing.

Exhibition Opportunities: The conference will feature a dedicated Exhibition Pavilion, providing commercial and non-commercial organizations an opportunity to showcase innovations, services, and technologies in vaccines, immunology, and global healthcare.

Potential Exhibitors Include:

• Pharmaceutical & Vaccine Companies
• Biotechnology Companies
• Clinical Research Organizations
• Medical Device & Diagnostic Manufacturers
• Hospitals and Healthcare Institutions
• Public Health Organizations
• Academic & Research Institutions
• Startups and Business Delegates

This exhibition offers valuable networking opportunities and enhanced brand visibility within the global vaccines and immunology community.

For exhibitor inquiries: meevents@memeetings.com

Advertisement: The official conference program serves as an essential resource for all attendees. Advertising within the program is an effective way to promote your services and gain lasting exposure.

For advertisement opportunities and pricing details, contact:

meevents@memeetings.com

Communication Guidelines

To ensure smooth communication:

Please add meevents@memeetings.com to your safe sender list.

• If you do not receive confirmation within 48 hours of registration or inquiry, kindly contact the conference coordinator.
• Always check your spam/junk folder before following up.

Group Registration Discounts

Discounted rates are available for group registrations. For eligibility criteria and pricing, please contact: meevents@memeetings.com

Important Registration Information

To ensure efficient coordination:

• Include your mobile phone number in your registration form and abstract submission.
• This allows us to provide timely updates and important notifications.

 For all general inquiries, please contact: meevents@memeetings.com

Abstract Submission Guidelines

1. Abstracts must be submitted through the official Abstract Submission link.
2. Abstracts should be written in English (250–300 words), along with a presenter biography (100–120 words).
3. Submissions are welcome across all areas of vaccines, immunology, infectious diseases, immunotherapy, epidemiology, and global health.
4. Presenting authors must provide: Full Name, Affiliation (Department, Institution/Hospital, Country), Phone Number, Email Address, and Photograph.
5. Co-authors must include full names and institutional affiliations.
6. All abstracts will be reviewed by the Conference Review Committee.
7. Accepted presenters must complete registration and pay the applicable conference fee.

Please ensure that your abstract title and affiliation details are accurate, as they will appear exactly as submitted in the final program and conference proceedings. Registration must be completed upon acceptance to confirm participation.

Visa Guidelines

World Vaccine Meet 2026 organizing committee hereby reiterates that we are NOT involved in VISA processing. We can assist by providing supporting documents like a Letter of invitation, Letter of Abstract Acceptance and Registration Payment Receipt.

You may be required to submit additional documents along with these documents to the embassy.

Letter of Invitation: The official Letter of Invitation is proof that your submitted paper and registration application are accepted by the conference committee board. It will be stated in English and may help you with your visa application.

Only registered participants will get an official letter of invitation

Attendees need to finish Registration & Authenticated information submission to get an official letter of invitation [i.e., Passport (Scan copy), DOB, Mobile Number, Physical Address and Photograph].

For more information Please Contact us at:   meevents@memeetings.com

Official Letters of Invitation will be provided only to attend the conference.